MX2017016302A - Agente terapeutico para tratar del sindrome de hunter y metodo de tratamiento. - Google Patents
Agente terapeutico para tratar del sindrome de hunter y metodo de tratamiento.Info
- Publication number
- MX2017016302A MX2017016302A MX2017016302A MX2017016302A MX2017016302A MX 2017016302 A MX2017016302 A MX 2017016302A MX 2017016302 A MX2017016302 A MX 2017016302A MX 2017016302 A MX2017016302 A MX 2017016302A MX 2017016302 A MX2017016302 A MX 2017016302A
- Authority
- MX
- Mexico
- Prior art keywords
- injection
- week
- once
- hunter syndrome
- therapeutic agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/06—Sulfuric ester hydrolases (3.1.6)
- C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)
Abstract
La presente invención se refiere a un agente terapéutico del síndrome de Hunter y, más específicamente, a un agente terapéutico del síndrome de Hunter que puede reducir el número de visitas al hospital de pacientes con síndrome de Hunter a dos veces al mes o menos, al contener una primera composición para inyectarse por vía intravenosa y una segunda composición para inyectarse por vía subcutánea, que presenta un efecto medicinal equivalente o mayor al de una inyección por vía intravenosa convencional una vez a la semana, los pacientes aumentan el cumplimiento de la toma de medicamentos en comparación con los agentes terapéuticos y los métodos de tratamiento convencionales, y permite un mayor bienestar y conveniencia para el paciente. De acuerdo con la presente invención, el método de co-inyección por vía IV/SC muestra un efecto terapéutico equivalente o superior comparado con el de una inyección por vía IV convencional una vez a la semana, mientras que permite a un paciente visitar el hospital con una frecuencia menor que una vez a la semana, como en visitas convencionales, reemplazando el método convencional de inyección por vía IV una vez a la semana, que requiere que el paciente visite el hospital una vez a la semana, por inyecciones por vía SC mediante las cuales un cuidador del paciente puede realizar directamente en casa una cantidad predeterminada de inyecciones por vía intravenosa. Esto va en contra de un concepto convencional de que el efecto terapéutico logrado por una inyección por vía SC no sería superior al efecto terapéutico logrado por una inyección por vía IV. Por lo tanto, la presente invención se refiere a un agente terapéutico y a un método de tratamiento del cual mejora espectacularmente un efecto del tratamiento del síndrome de Hunter con respecto al de una tecnología convencional.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562187867P | 2015-07-02 | 2015-07-02 | |
KR1020150187297A KR20170004814A (ko) | 2015-07-02 | 2015-12-28 | 헌터증후군 치료제 |
PCT/KR2016/007203 WO2017003270A1 (ko) | 2015-07-02 | 2016-07-04 | 헌터증후군 치료제 및 치료방법 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017016302A true MX2017016302A (es) | 2018-03-23 |
Family
ID=57833331
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017016302A MX2017016302A (es) | 2015-07-02 | 2016-07-04 | Agente terapeutico para tratar del sindrome de hunter y metodo de tratamiento. |
Country Status (15)
Country | Link |
---|---|
US (2) | US10561713B2 (es) |
EP (1) | EP3318267B1 (es) |
JP (2) | JP6606199B2 (es) |
KR (3) | KR20170004814A (es) |
CN (1) | CN107921091A (es) |
BR (1) | BR112018000051A2 (es) |
CA (1) | CA2990370C (es) |
CL (1) | CL2018000002A1 (es) |
CO (1) | CO2018000196A2 (es) |
EA (1) | EA038110B1 (es) |
ES (1) | ES2866957T3 (es) |
HK (1) | HK1252663A1 (es) |
MX (1) | MX2017016302A (es) |
PE (1) | PE20190351A1 (es) |
PL (1) | PL3318267T3 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2988601C (en) | 2015-07-02 | 2021-12-07 | F. Hoffmann-La Roche Ag | Bicyclic lactams and methods of use thereof |
EP3526219B1 (en) | 2016-10-17 | 2021-12-15 | F. Hoffmann-La Roche AG | Bicyclic pyridone lactams and methods of use thereof |
US11072607B2 (en) | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
MA50746A (fr) | 2017-10-02 | 2020-08-12 | Denali Therapeutics Inc | Protéines de fusion comprenant des enzymes d'enzymothérapie substitutive |
EP3781571B1 (en) | 2018-04-20 | 2024-01-17 | F. Hoffmann-La Roche AG | N-[4-oxo-2,3-dihydro-pyrido[3,2-b][1,4]oxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazole-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs) |
KR20190136271A (ko) | 2018-05-30 | 2019-12-10 | 주식회사 녹십자 | 대뇌 측뇌실 투여에 의해 헌터증후군을 치료하기 위한 방법 및 조성물 |
CA3116004A1 (en) * | 2018-10-11 | 2020-04-16 | Indivior Uk Limited | Buprenorphine to treat respiratory depression |
EP3826664A4 (en) * | 2019-02-06 | 2022-10-26 | Sangamo Therapeutics, Inc. | METHOD FOR THE TREATMENT OF TYPE I MUCOPOLYSACCHARIDOSES |
JP2023529686A (ja) | 2020-06-16 | 2023-07-11 | ノベルファーマ株式会社 | グルタル酸尿症治療用組成物及びこの投与方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101183262B1 (ko) * | 2009-04-22 | 2012-09-14 | (주)알테오젠 | 체내 지속성을 유지함으로 체내 반감기가 증가된 단백질 또는 펩티드 융합체, 및 이를 이용하여 체내 반감기를 증가시키는 방법 |
US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
EP2588130B1 (en) * | 2010-06-25 | 2016-08-17 | Shire Human Genetic Therapies, Inc. | Cns delivery of therapeutic agents |
RU2660348C2 (ru) * | 2010-06-25 | 2018-07-05 | Шир Хьюман Дженетик Терапис, Инк. | Способы и композиции для доставки в цнс идуронат-2-сульфатазы |
KR101158673B1 (ko) * | 2011-06-24 | 2012-07-03 | 주식회사 지씨바이오 | 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법 |
AU2012358223B2 (en) * | 2011-12-23 | 2018-01-18 | Takeda Pharmaceutical Company Limited | Treatment of cognitive impairment of Hunter syndrome by intrathecal delivery of iduronate-2-sulfatase |
WO2013148277A1 (en) * | 2012-03-30 | 2013-10-03 | Shire Human Genetic Therapies, Inc. | Subcutaneous administration of iduronate- 2-sulfatase |
JP2015013624A (ja) * | 2013-07-08 | 2015-01-22 | 船井電機株式会社 | 手動推進器具 |
-
2015
- 2015-12-28 KR KR1020150187297A patent/KR20170004814A/ko not_active Application Discontinuation
-
2016
- 2016-07-04 ES ES16818303T patent/ES2866957T3/es active Active
- 2016-07-04 CA CA2990370A patent/CA2990370C/en active Active
- 2016-07-04 JP JP2017568199A patent/JP6606199B2/ja active Active
- 2016-07-04 US US15/738,017 patent/US10561713B2/en active Active
- 2016-07-04 PE PE2017002893A patent/PE20190351A1/es unknown
- 2016-07-04 EP EP16818303.6A patent/EP3318267B1/en active Active
- 2016-07-04 KR KR1020187001448A patent/KR20180015256A/ko active Search and Examination
- 2016-07-04 EA EA201890182A patent/EA038110B1/ru unknown
- 2016-07-04 MX MX2017016302A patent/MX2017016302A/es unknown
- 2016-07-04 KR KR1020197036839A patent/KR102213055B1/ko active IP Right Grant
- 2016-07-04 PL PL16818303T patent/PL3318267T3/pl unknown
- 2016-07-04 CN CN201680038666.3A patent/CN107921091A/zh active Pending
- 2016-07-04 BR BR112018000051-5A patent/BR112018000051A2/pt active Search and Examination
-
2018
- 2018-01-02 CL CL2018000002A patent/CL2018000002A1/es unknown
- 2018-01-11 CO CONC2018/0000196A patent/CO2018000196A2/es unknown
- 2018-09-18 HK HK18111970.1A patent/HK1252663A1/zh unknown
-
2019
- 2019-09-05 JP JP2019161855A patent/JP6858231B2/ja active Active
- 2019-11-27 US US16/698,403 patent/US20200093899A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CO2018000196A2 (es) | 2018-03-28 |
EP3318267B1 (en) | 2021-02-24 |
CA2990370A1 (en) | 2017-01-05 |
CA2990370C (en) | 2022-05-17 |
ES2866957T3 (es) | 2021-10-20 |
BR112018000051A2 (pt) | 2018-09-04 |
US20180303914A1 (en) | 2018-10-25 |
JP2020019775A (ja) | 2020-02-06 |
EP3318267A4 (en) | 2019-02-27 |
US20200093899A1 (en) | 2020-03-26 |
KR20180015256A (ko) | 2018-02-12 |
EA038110B1 (ru) | 2021-07-07 |
EA201890182A1 (ru) | 2018-06-29 |
HK1252663A1 (zh) | 2019-05-31 |
US10561713B2 (en) | 2020-02-18 |
JP6606199B2 (ja) | 2019-11-13 |
KR102213055B1 (ko) | 2021-02-08 |
PL3318267T3 (pl) | 2021-07-12 |
PE20190351A1 (es) | 2019-03-07 |
CN107921091A (zh) | 2018-04-17 |
CL2018000002A1 (es) | 2018-06-29 |
KR20190141026A (ko) | 2019-12-20 |
EP3318267A1 (en) | 2018-05-09 |
KR20170004814A (ko) | 2017-01-11 |
JP2018519326A (ja) | 2018-07-19 |
JP6858231B2 (ja) | 2021-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2017016302A (es) | Agente terapeutico para tratar del sindrome de hunter y metodo de tratamiento. | |
EP4233861A3 (en) | Compositions for treatment of essential tremor | |
MX2013004406A (es) | Tratamiento de diabetes mellitus usando inyecciones de insulina administradas con intervalos variables de inyeccion. | |
MX2018005256A (es) | Formulaciones inyectables de toxina botulinica y metodos de uso de las mismas que tienen efecto terapautico o cosmetico de larga duracion. | |
EA201591687A1 (ru) | Индукционная терапия ритуксимабом с последующим лечением с использованием глатирамера ацетата | |
NZ717504A (en) | Methods of treatment of cancer by continuous infusion of coenzyme q10 | |
EA201490377A1 (ru) | Лечение рассеянного склероза комбинацией лаквинимода и глатирамера ацетата | |
SG10201810888XA (en) | Compositions and methods comprising bupropion or related compounds and dextromethorphan | |
PH12020500555A1 (en) | Esketamine for the treatment of depression | |
MX2017008569A (es) | Derivados de glucagon con estabilidad mejorada. | |
CY1122508T1 (el) | Παρασκευευασματα για θεραπεια gd2 θετικου καρκινου | |
PH12020550821A1 (en) | Injectable botulinum toxin formulations and methods of use thereof having high response rate and long effect duration | |
MX2016006179A (es) | Formulaciones de capsaicinoides basadas en agua y metodos de manufactura y uso. | |
EA201501054A1 (ru) | Лечение миопатий и нейродегенеративных заболеваний, связанных с агрегацией белков, путём парентерального введения трегалозы | |
MX2018013715A (es) | Composiciones acuosas de capsaicinoides que comprenden un analgesico y un vehiculo acuoso, y uso de las mismas para el tratamiento del dolor. | |
MX2016000220A (es) | Regulacion del metabolismo de glucosa usando anticuerpos anti-cgrp. | |
RU2014103543A (ru) | Ботулотоксины для применения в способе лечения жировых отложений | |
MX2021011230A (es) | Administracion subcutanea de nanoparticulas que comprenden un inhibidor del objetivo de la rapamicina en mamiferos (mtor) y albumina para tratamiento de enfermedades. | |
JP2017524721A5 (es) | ||
MX2020007222A (es) | Metodos para el tratamiento de afecciones inflamatorias de la piel. | |
MX2018007377A (es) | Composicion de acido hialuronico para inyecciones en el pene. | |
PH12020550066A1 (en) | METHOD FOR TREATING TNFa-RELATED DISEASE | |
EA201700347A2 (ru) | Средство для эффективного купирования острого и/или хронического болевого синдрома и способ его применения | |
MX2021001502A (es) | Tratamiento de verrugas. | |
BR112022004723A2 (pt) | Formulações de insulina e glucagon injetáveis por via subcutânea e métodos de administração |